Takeda Readying To Launch Acid Reflux Med Kapidex Within A Month
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese drug maker looks to dexlansoprazole to help offset loses when Prevacid and anti-diabetic Actos go off patent this year.
You may also be interested in...
New Zealand PHARMAC Proposes Lifting Restrictions On Merck’s Fosamax; Reduces Subsidy For EC Aspirin
PERTH, Australia - New Zealand's Pharmaceutical Management Agency has proposed lifting some of the restrictions on drugs classified for musculoskeletal system therapies, effective March 1, the agency announced Jan. 12
U.S. FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
U.S. FDA has set a new action date of June 26, 2009 for Takeda's dipeptidyl peptidase IV inhibitor alogliptin, after missing the original user fee deadline of Oct. 27, the company announced Dec. 24
Takeda, CanBas Begin Phase II Trials For Malignant Pleural Mesothelioma Drug
TOKYO - Osaka-based Takeda and its U.S. subsidiary Millennium, jointly with a Japanese pharmaceutical venture, CanBas Co., have begun Phase II trials of malignant pleural mesothelioma drug CBP501 in the United States. The drug's advancement could eventually save millions of people that have been exposed to deadly asbestos, the company said